Mevrometostat (M) plus enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomised dose-expansion study
Year: 2025
Type: article
Source: European Urology Open Science
Authors: M.T. Schweizer, M. Calvo, V. Moreno, B. Mellado, D. Castellano, Q. Wei, J. Carles, B. Garmezy, C. Kwak, I. Ługowska, K. Penkov, G. de Velasco, N.D. Shore, L. Liu, R. Mittapalli, J. Tougias, C. Andreu-Vieyra, N. Soman, T. Alonso Gordoa
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,800
OpenAlex ID: W4416170304
FWCI:
Cites:
Cited by:
Related to: